More options for HIV.
A combination of atovaquone-azithromycin (AT-AZ) is as effective as trimethoprim-sulfamethoxazole (TMP-SMZ) for the prevention of serious bacterial infections in children with HIV aged 3 months to 19 years, said Walter T. Hughes, M.D., of St. Jude Children's Research Hospital, Memphis, and his colleagues.
TMP-SMZ is widely used against bacterial infections in children with and without HIV, but some children experience adverse reactions and need an alternative treatment.
In a randomized, double-blind, placebo-controlled study, 366 children were followed for an average of 3 years (Clin. Infect. Dis. 2005;40:136-45). Serious bacterial infections were 12.9/100 personyears in the AT-AZ group, compared with 18.5/100 person-years in the TMP-SMZ group.
Hematologic problems were the most common adverse events, occurring in 39% of the AT-AZ children and 37% of the TMP-SMZ children. While the high cost of atovaquone-azithromycin prevents its use in most cases, it presents a viable alternative for children who experience adverse effects from TMP-SMZ, researchers said.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||prevention of infectious diseases in children|
|Publication:||Family Practice News|
|Article Type:||Brief Article|
|Date:||Jul 15, 2005|
|Previous Article:||Tularemia from hamster bite.|
|Next Article:||Teens and tobacco addiction.|